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Abstract
Vaccination with plasmid DNA encoding Ag85A from M. bovis BCG can partially protect C57BL/6 mice against a subsequent
footpad challenge with M. ulcerans. Unfortunately, this cross-reactive protection is insufficient to completely control the
infection. Although genes encoding Ag85A from M. bovis BCG (identical to genes from M. tuberculosis) and from M. ulcerans
are highly conserved, minor sequence differences exist, and use of the specific gene of M. ulcerans could possibly result in a
more potent vaccine. Here we report on a comparison of immunogenicity and protective efficacy in C57BL/6 mice of Ag85A
from M. tuberculosis and M. ulcerans, administered as a plasmid DNA vaccine, as a recombinant protein vaccine in adjuvant
or as a combined DNA prime-protein boost vaccine. All three vaccination formulations induced cross-reactive humoral and
cell-mediated immune responses, although species-specific Th1 type T cell epitopes could be identified in both the NH2-
terminal region and the COOH-terminal region of the antigens. This partial species-specificity was reflected in a higher—
albeit not sustained—protective efficacy of the M. ulcerans than of the M. tuberculosis vaccine, particularly when
administered using the DNA prime-protein boost protocol.
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Introduction
Buruli ulcer (BU), also known as Bairnsdale ulcer, is an
infectious, necrotizing skin disease caused by Mycobacterium ulcerans
(M. ulcerans) occurring mostly in tropical and subtropical areas.
Cases have been reported in several countries in West and Central
Africa, in Central and South America, in Southeast Asia and in
Australia. BU is emerging as a serious health problem, especially in
West Africa, where it is the third leading cause of mycobacterial
disease in immunocompetent people, after tuberculosis and
leprosy. In some countries in Africa, thousands of cases occur
annually and in these areas BU has supplanted leprosy to become
the second most important human mycobacterial disease. The
natural history of M. ulcerans infection and subsequent develop-
ment of BU is not completely elucidated. M. ulcerans bacteria have
been found in endemic areas in stagnant water or slowly moving
water sources and in aquatic snails and carnivorous insects [1,2].
So far, person to person transmission has not been reported. The
infection causes initially a painless nodular swelling which can
eventually develop into an extensive necrotizing lesion. M. ulcerans
has the particularity to produce a family of toxin molecules, the so-
called mycolactone (ML), polyketides that can suppress the
immune system and destroy skin, underlying tissue and bone,
causing severe deformities [3–5]. ML suppresses the in vitro TNF-a
production by murine macrophages infected with M. ulcerans (4)
and it strongly affects the maturation and the migratory properties
of DC [5]. On the other hand, ML does not seem to affect the
production of the inflammatory cytokine MIP-2, involved in the
recruitment of neutrophils (4). M. ulcerans has an initial intracellular
infection stage but virulent ML producing strains induce apoptosis
of the infected cells and can subsequently be found extracellularly
[3,6]. Only few Mycobacterium species produce mycolactone toxins
[7]. M. ulcerans isolates from different geographical areas produce
different types of mycolactone, i.e. mycolactone A/B, C, D, E and
F [8,9].
The nature of immune protection against M. ulcerans infection
remains unclear. In general, resistance to intracellular bacteria is
primarily mediated by T cells with pivotal roles of Th1 type
cytokines IFN-c and TNF-a and this apparently is the case for M.
ulcerans infection as well [10]. Progression of active Buruli ulcer is
characterized by gradual down regulation of systemic and local
Th1 type immune responses. Peripheral blood mononuclear cells
from Buruli ulcer patients show reduced lymphoproliferation and
IFN-c production in response to specific stimulation with M.
ulcerans [11–13]. Reduced IFN-c response does not seem to be
caused by decreased interleukin-12 production [14]. Also, semi-
quantitative RT-PCR analysis demonstrated high IFN-c and low
IL-10 levels in early, nodular lesions whereas low IFN-c and high
IL-10 mRNA levels are observed in late ulcerative lesions [13].
Using a similar RT-PCR comparison of granulomatous versus
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expression of IL-12p35, IL-12p40, Il-15, IL-1b and TNF-a in
patients from the former group and higher expression levels of IL-
8 (human homologue of MIP-2) in the latter group [15]. Finally,
Kiszewski et al have also confirmed that in ulcerative lesions
without granuloma, there is increased expression of IL-10 and
higher bacillary counts. [16].
It is not yet clear whether antibodies play a protective role
against BU but the humoral immune response during M. ulcerans
infection may be useful for serodiagnosis of BU. In contrast to
tuberculosis and leprosy, immunoglobulin IgG antibody produc-
tion against M ulcerans can be found even in early stages of
infection [17]. IgG antibodies cannot be used to readily discern
between patients and family controls, but primary IgM antibody
responses against M. ulcerans culture filtrate proteins can be
detected in sera from 85% of confirmed BD patients and only in a
small proportion in sera from healthy family controls [18].
Antibody responses against the M. ulcerans homologue of the M.
leprae 18-kDa small heat shock protein -that has no homologues in
M. bovis and M. tuberculosis- can be used as serological marker for
exposure to M. ulcerans [19].
BU results in considerable morbidity. Because of the late
detection of the disease, treatment is principally by excision of the
lesion, sometimes necessitating skin grafting [20]. WHO is
currently recommending combined rifampicin and streptomycin
treatment of nodules for eight weeks in the hope of reducing the
need for surgery [21,22]. Unfortunately, there is no specific
vaccine against BU for the moment [23]. M. bovis BCG (Bacille
Calmette et Gue ´rin) vaccine, used for the prevention of
tuberculosis, has been reported to offer a short-lived protection
against the development of skin ulcers [24–26] and to confer
significant protection against disseminated cases of BU, e.g.
osteomyelitis, both in children and in adults [27,28]. The precise
M. ulcerans antigens that induce a protective immune response are
poorly defined. The complete genome sequence of M. ulcerans has
recently been published and will hopefully help to advance
research and identification of relevant genes [29]. The 65 kD heat
shock protein is expressed in considerable amounts by M. ulcerans
bacilli in vitro and in vivo, and is immunogenic for both B and T
cells in mice. Nevertheless, vaccination of mice with plasmid DNA
encoding Hsp65 from M. leprae, having 96% sequence identity
with Hsp65 from M. ulcerans, limited only weakly the progression
of experimental M. ulcerans infection in tail [30]. We have
previously reported that vaccination with BCG or with plasmid
DNA encoding Ag85A from M. bovis BCG can partially protect B6
mice against footpad challenge with M. ulcerans [31]. Antigen 85 is
a major secreted component in the culture filtrate of many
mycobacteria such as M. bovis BCG, M. tuberculosis and M. avium
subsp. paratuberculosis [32]. The antigen 85 complex (Ag85) of M.
tuberculosis is a family of three proteins, Ag85A, Ag85B and Ag85C,
which are encoded by three distinct but highly paralogous genes
and that display an enzymatic mycolyl-transferase activity,
involved in cell wall synthesis [33,34]. Members of the Ag85
family rank among the most promising tuberculosis vaccine
candidates, and are actually being tested in clinical trials,
formulated as Hybrid-1 fusion protein of Ag85B with ESAT-6
or as recombinant Modified Vaccina Ankara virus encoding
Ag85A booster vaccine of BCG [35,36]. We have previously
sequenced the gene encoding Ag85A from M. ulcerans and reported
that it shares 84.1% amino acid sequence identity and 91%
conserved residues with the gene encoding Ag85A from M.
tuberculosis (which is identical to the Ag85A gene of M. bovis BCG)
[31]. The genes encoding Ag85B and Ag85C of M. ulcerans have
recently been sequenced as well and – as for M. tuberculosis- were
localized on different loci in the genome [29].
Here, we report on a comparison of the immunogenicity and
protective efficacy of vaccines encoding Ag85A from M. tuberculosis
and from M. ulcerans. Vaccines were administered as plasmid
DNA, purified protein in adjuvant or in a DNA prime-protein
boost protocol. We and others have previously reported that DNA
priming followed by protein boosting is an effective means to
increase the potential of DNA vaccines [37–40].
Materials and Methods
Mice
C57BL/6 mice were bred in the Animal Facilities of the IPH-
Pasteur Institute Brussels, from breeding couples originally
obtained from Bantin & Kingman (UK). Mice were 8–10 weeks
old at the start of the experiments. Female mice were used for
immune analysis and male mice for the protection studies. This
study has been reviewed and approved by the local Animal Ethics
Committee (file number 030212/05).
Mycobacterial strains
Virulent M. ulcerans type 1 strain 04-855 from a Benin patient
was isolated at the Institute for Tropical Medicine in Antwerp,
Belgium. Bacteria grown on Lo ¨wenstein-Jensen medium were
maintained and amplified in vivo in footpad of the mice. M. bovis
BCG strain GL2 was grown for 2 weeks as a surface pellicle at
37uC on synthetic Sauton medium and homogenized by ball mill
as described before [41].
Plasmid DNA constructions
Plasmid DNA encoding the mature 32 kD Ag85A from M.
tuberculosis in V1J.ns-tPA vector was prepared as described before
[31,42]. The gene encoding Ag85A from M. ulcerans was amplified
by PCR without its mycobacterial signal sequence using BglII
restriction site containing primers and ligated into the same V1J.ns-
tPA vector. The primers used were 59-GGAAGATCTT-
GAGCGCTTGGTACTAGGC-39 (forward) and 59-GGAA-
GATCTTTTCGCGGCCGGGCCTGCCGGTGGA-39 (reverse).
In these plasmids the Ag 85A gene is expressed under the control of
the promoter of IE1 antigen from cytomegalovirus, including intron
Author Summary
Buruli ulcer (BU) is an infectious disease characterized by
deep, ulcerating skin lesions, particularly on arms and legs,
that are provoked by a toxin. BU is caused by a microbe
belonging to the same family that also causes tuberculosis
and leprosy. The disease is emerging as a serious health
problem, especially in West Africa. Vaccines are considered
to be the most cost-effective strategy to control and
eventually eradicate an infectious disease. For the mo-
ment, however, there is no good vaccine against BU, and it
is still not fully understood which immune defence
mechanisms are needed to control the infection. The
identification of microbial components that are involved in
the immune control is an essential step in the develop-
ment of an effective vaccine. In this paper, we describe the
identification of one of these microbial components, i.e.,
antigen 85A, a protein involved in the integrity of the cell
wall of the microbe. Our findings obtained in a mouse
model now need to be extended to other experimental
animals and later to humans. Combination with a vaccine
targeting the toxin may be a way to strengthen the
effectiveness of the vaccine.
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plasminogen activator.
Recombinant Ag85A proteins
Hexa-histidine tagged Ag85A protein from M. tuberculosis was
purified from recombinant E. coli as described before [43]. The
gene encoding the mature Ag85A protein from M. ulcerans was
amplified by PCR from V1J.ns.tPA-85A vector. The primers
used were 59-CGCGGATCCGCGTTTTCGCGGCCGGGCC-
TGCCGTGGAA-39 (forward) and 59-CCCAAGCTTGGGC-
TAGGCGCCCTGGGTGTCACCG-39 (reverse) with respectively
BamHI and Hind III restriction sites. Ag85A gene was amplified
without its mycobacterial signal sequence. Cloning in expression
vectorpQE-80L (QIAGEN),containingan NH2-terminal histidine-
tag coding sequence, and purification were performed as described
before [32]. Briefly, positives clones were screened on LB-ampicillin
medium after ligation of the gene in the vector and transformation
of E. coli DH5a cells. For expression, Top-10F’ E. coli (Invitrogen)
cells were transformed with plasmid encoding the 85A sequence.
Recombinant protein was purified by immobilized metal affinity
chromatography (IMAC) using gravity flow. The endotoxin level
measured with the LAL kinetic chromogenic assay, was inferior to
10 EU/ml (endotoxin units per millilitre) or 0.03 EU/mg of purified
protein (Cambrex Bioscience, New Jersey, America).
Peptide synthesis
Peptides spanning the entire mature 295 amino-acid Ag85A
sequence of M. tuberculosis were synthesized as 20-mers, with the
exception of the 18-mer spanning aa 35–53 and the 21 mer-
peptide spanning amino acids 275–295 [44]. Peptides spanning
the entire 294-amino acid Ag85A sequence of M. ulcerans were
synthesized as 20-mers. All peptides were purchased from Ansynth
Service B.V., The Netherlands.
Vaccination protocols
In experiment 1, B6 mice were anesthesized by intraperitoneal
injection of ketamine-xylazine and injected three times intramus-
cularly (i.m) in both quadriceps muscles with 2650 mg of control
V1J.ns-tPA (empty vector), V1J.ns-tPA-Ag85A DNA from M.
ulcerans or from M. tuberculosis (abbreviated as Ag85A-DNA Mu
and Ag85A-DNA Mtb in the figures). For protein immunization,
mice were injected three times subcutaneously (s.c) in the back
with 10 mg of purified recombinant Ag85A (abbreviated as
rec85A-Mu and rec85A-Mtb in the figures), emulsified in Gerbu
adjuvant, i.e. water miscible, lipid cationic biodegradable
nanoparticles, completed with immunomodulators and GMDP
glycopeptide (GERBU Biochemicals). For the DNA prime-protein
boost, mice were immunized twice i.m. with Ag85A DNA from M.
ulcerans or from M. tuberculosis and boosted s.c. with 20 mgo f
recombinant Ag85A protein respectively from M. ulcerans or M.
tuberculosis in Gerbu adjuvant (abbreviated as Ag85A-DNA/recMu
and Ag85A-DNA/recMtb in the figures). All mice received the
two first injections at 3 week intervals and the third injection was
given two months later. For BCG vaccination, mice were injected
intravenously, in a lateral tail vein, at the time of the first DNA
injection with 0.2 mg (corresponding to 10
6 CFU) of freshly
prepared live M. bovis BCG [41].
In experiment 2, B6 mice were injected intramuscularly (i.m)
three times, at 3 weeks intervals, in both quadriceps with 2650 mg
of control V1Jns.tPA DNA or plasmid DNA encoding 85A from
M. ulcerans or from M. tuberculosis. For protein immunization, mice
were injected three times subcutaneously (s.c) in the back with
10 mg of purified recombinant Ag85A from M. ulcerans or from M.
tuberculosis, emulsified in monophosphoryl lipid A (MPL-A) from
Salmonella enterica serovar Minnesota (Ribi ImmunoChem Re-
search, Hamilton, Mont)) solubilized in triethanolamine. For the
DNA prime-protein boost, mice were immunized twice i.m. with
Ag85A DNA from M. ulcerans or from M. tuberculosis and boosted
s.c. with 20 mg of purified recombinant Ag85A protein respectively
from M. ulcerans or from M. tuberculosis in MPL-A.
Infection
Naı ¨ve and vaccinated B6 mice were infected with M. ulcerans 3
months (Exp1) or 6 weeks (Exp2) after the last vaccination. 10
5
acid fast bacilli (AFB), obtained by in vivo passage in footpad, were
injected in the right footpad of the vaccinated mice. The number
of bacilli injected, suspended in Dubos Broth Base medium (Difco),
was determined by counting under a microscope after Ziehl
Neelsen staining. Viability of the M. ulcerans inoculum was checked
by plating on 7H11 Middlebrook agar, supplemented with oleic-
acid-albumin-dextrose-catalase enrichment medium. Yellow colo-
nies were counted after 8 weeks of incubation at 32uC. The
number of Colony Forming Units corresponded to the number of
AFB.
Cytokine production
Vaccinated mice were sacrificed 3 weeks after the third
immunization (Experiment 1). Spleens were removed aseptically
and homogenized in a loosely fitting Dounce homogenizer.
Leucocytes (4610
6 WBC/ml) from four mice per group were
cultivated at 37uC in a humidified CO2 incubator in round-
bottom micro well plates individually or pooled (as indicated) and
analyzed for Th1 type cytokine response to purified recombinant
his-tagged Ag85A (5 mg/ml), and synthetic peptides from M.
ulcerans or M. tuberculosis (10 mg/ml). Supernatants from at least
three wells were pooled and stored frozen at 220uC. Cytokines
were harvested after 24 h (IL-2) and 72 h (IFN-c), when peak
values of the respective cytokines can be measured.
IL-2 assay
Interleukin-2 (IL-2) activity was determined in duplicate on 24 h
culture supernatants using a bio-assay with IL-2 dependent CTLL-
2 cells as described before [45]. IL-2 levels are expressed as mean
counts per minute (cpm). Assay sensitivity is 10 pg/ml. A typical
international standard curve of this assay has been published
before [46].
IFN-c assay
Interferon-c (IFN-c) activity was quantified by sandwich ELISA
using coating antibody R4-6A2 and biotinylated detection
antibody XMG1.2 obtained from Pharmingen. The standard
murine recombinant IFN-c used was obtained from R&D. The
sensitivity of the assay is 10 pg/ml.
ELISA
Sera from immunized mice were collected by tail bleeding 3
weeks after the third vaccination. Levels of M. ulcerans specific total
anti-Ag85A Igk antibodies (Abs) were determined by direct
enzyme-linked immunosorbant assay (ELISA) in sera from
individual mice (four/group). The concentration of Ab was
expressed by the optical density at a dilution of 1/100 of the
sera. For isotype analysis, peroxidase-labeled rat anti-mouse
immunoglobulin G1 (IgG1) and IgG2b (Experimental Immunol-
ogy Unit, Universite ´ Catholique de Louvain, Brussels, Belgium)
were used. Isotype titers were expressed as dilution endpoints (last
serum dilution with an optical density (OD) value higher than a
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standard deviations (SD) of the secondary antibody only [42].
Protection analysis
In experiment 1 (Gerbu adjuvant), protection was evaluated by
enumeration of Acid Fast Bacilli (AFB) nine weeks after footpad
infection. Briefly, the skin and bones were removed from infected
foot pad. Tissues were homogenized in a Dounce homogenizer
and suspended in 2 ml of Dubos broth based medium containing
glass bead. The number of AFB in 20 fields (surface of 1 field:
0.037994 mm
2620 with the 22 mm ocular diameter used) was
counted on microscope slides after Ziehl-Neelsen staining. In
experiment 2 (MPL-A adjuvant), protection was evaluated by
monitoring foot pad swelling after M. ulcerans infection. The
swelling was measured with a calibrated Oditest apparatus with a
resolution of 0.01 mm as described previously [47]. Animals were
euthanized when footpad swelling exceeded 4mm according to the
rules of the local ethical commission.
Statistical analysis
For cytokine production analysis, antibody production and AFB
counting, statistical analysis was made according to one-way
ANOVA test. Subsequent multiple comparison between the 7
different groups of animals and the antigens used was made by a
Tukey’s correction test. Statistical results are represented in the
figure by *** (P,0.001), ** (P,0.01) and * (P,0.05). For the
comparison of survival curves, logrank test was used.
Results
Partially species-specific Th1 type cytokine production in
spleen cell cultures from B6 mice vaccinated with Ag85A-
DNA, Ag85A protein or with a DNA prime-protein boost
Spleen cells from mice vaccinated with the three different
vaccine formulations produced significant levels of IL-2 (Figure 1A)
and IFN-c (Figure 1B) after in vitro stimulation with purified
recombinant Ag85A from M. ulcerans or from M. tuberculosis. As
expected from the 91% sequence similarity between both antigens,
highly cross-reactive immune responses were observed, mice
vaccinated with M. ulcerans vaccines recognizing the M. tuberculosis
antigen and vice versa. Nevertheless, a certain level of species
specificity was observed, particularly in the IL-2 responses.
Confirming previous results obtained with a M. tuberculosis DNA
vaccine [37], boosting plasmid DNA vaccinated mice with purified
M. ulcerans protein increased significantly Ag 85A specific IL-2 and
IFN-c responses.
M. ulcerans Ag85A specific antibody production in mice
vaccinated with Ag85A-DNA, Ag85A protein or with a
DNA prime-protein boost
Significant cross-reactive antibody responses were induced
against Ag85A from M. ulcerans (and from M. tuberculosis, data
not shown) in mice vaccinated with the M. ulcerans and M.
tuberculosis vaccines (Figure 2).
Antibody responses in DNA vaccinated mice demonstrated
considerable individual variation, and were markedly increased by
the protein boost. Vaccination with purified protein in Gerbu
adjuvant was also very effective in inducing high level antibody
production. DNA vaccination induced very little IgG1 isotype
antibodies but biased predominantly an IgG2b isotype response,
confirming the well known Th1 inducing properties of intramus-
cular plasmid DNA. In contrast, vaccination with protein
emulsified in Gerbu adjuvant induced antibodies of both IgG1
and of IgG2b isotype. Confirming previous findings, DNA prime-
protein boost vaccination resulted in increased and less variable
antibody titers of both isotypes [37]. Vaccination with recombinant
85A protein or with the DNA prime /protein boost protocol
induced significantly higher levels of total IgG and IgG1 antibodies
as compared to plasmid DNA vaccination alone (P,0.001).
Identification of species-specific H-2
b restricted Th1 T cell
epitopes in M. ulcerans Ag85A
Despite the high level of sequence similarity (91%) between
Ag85A from M. tuberculosis and M. ulcerans but in view of the partial
species-specific Th1 type immune responses observed in the
previous experiment, we decided to characterize the H-2
b restricted
immunodominant T cell epitopes, using synthetic 20-mer peptides
spanning the entire mature sequence of Ag85A from M. ulcerans and
from M. tuberculosis. Figure 3 shows the IL-2 and IFN-c production
induced in response to M. ulcerans peptides in mice vaccinated with
M. ulcerans DNA (white bars) or M. tuberculosis DNA (black bars).
Spleen cells from B6 mice vaccinated with M.ulcerans-Ag85A DNA
producedsignificantlevelsofIL-2(Figure3A)andIFN-c (Figure3B)
when stimulated with M. ulcerans peptides both from the NH2-
terminaland COOH-terminalpart oftheprotein,whereasIL-2and
IFN-c responses of B6 mice vaccinated with the M. tuberculosis
plasmid were almost exclusively directed against M. ulcerans peptide
spanning aa 241–260. M. ulcerans DNA vaccinated mice also
recognized this peptide very effectively. Responses against the NH2-
terminal peptides spanning aa 61–80 and 81–100 of M. ulcerans-
Ag85A were only observed in M. ulcerans DNA vaccinated mice,
indicating that this NH2-terminal region was responsible for the
partial species-specificity. This confirmed a previous finding (Inserts
in Figures 3A and 3B) on species-specific T cell responses induced
following in vitro stimulation with a purified, partial M. ulcerans
Ag85A protein, spanning aa 17–150 in mice vaccinated with DNA
encoding Ag85A from M. ulcerans or M. tuberculosis. IL-2 and IFN-c
responses against M. ulcerans peptide spanning aa 261–280 were also
species-specific and only detected in mice immunized with the M.
ulcerans vaccine.
Responses against M. tuberculosis peptides showed a reciprocal
pattern (Figure 4). Confirming previous findings [37] M. tuberculosis
peptide spanning aa 261–280 was very well recognized in M.
tuberculosis DNA vaccinated mice (Figure 4A and 4B). It was also
recognized by M. ulcerans vaccinated mice. Both DNA vaccinated
groups also reacted against M. tuberculosis peptide spanning aa
241–260, previously found to contain the immunodominant H-2
b
restricted epitope recognized in BCG vaccinated and M. tuberculosis
infected B6 mice (10). Responses against this M. tuberculosis peptide
were even higher in M. ulcerans than in M. tuberculosis DNA
vaccinated mice. IFN-c responses against M. tuberculosis peptides
spanning aa 121–140 and 141–160 were only observed in mice
vaccinated with the M. tuberculosis DNA, whereas a cross-reactive
immune responses was found against M. tuberculosis peptide
spanning aa 81–100. A sequence comparison of identified
immunodominant Th1 peptides of Ag85A from M. ulcerans and
from M. tuberculosis, showing conserved and non-conserved amino
acid changes is presented in Table 1.
Reduced M. ulcerans replication in footpad of mice
vaccinated with Ag85A-DNA, Ag85A protein and with a
DNA prime-protein boost
Mice were challenged three months after the third vaccination
with 10
5 AFB of M. ulcerans in the footpad. Nine weeks later, when
a significant swelling of the footpad appeared in the control mice
vaccinated with empty vector, all animals were sacrificed and the
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Neelsen staining. As shown in Figure 5, a significant and strong
reduction in the number of M. ulcerans AFB was observed in mice
previously immunized with all three types of vaccine. Vaccination
with specific M. ulcerans antigen using the DNA prime-protein
boost protocol with Gerbu adjuvant conferred the highest
protection with an almost one-hundred fold reduction in number
of AFB as compared to the control group. This protection was
comparable in magnitude to the protection conferred by the BCG
vaccine. Difference between the vaccinated groups was not
significant (ANOVA test; p.0.05).
Prolonged survival after M. ulcerans challenge in mice
vaccinated with Ag85A-DNA or with a DNA prime-
protein boost
In a second experiment, protective efficacy of the vaccines was
determined by weekly monitoring appearance and size of footpad
swelling and survival as previously reported [47]. Mice were
euthanized when footpad swelling was .4 mm. In this experiment
mice were challenged with 10
5 AFB of M. ulcerans 04-855 at 6
weeks after the last immunization. The evolution of footpad
swelling is shown in Figure 6A and 6C whereas the survival curves
are represented in Figure 6B and 6D. In mice vaccinated with
empty control vector, footpad size started to increase 5 weeks after
M. ulcerans infection whereas in BCG vaccinated mice, footpad
swelling was delayed for 7–8 weeks (Figures 6A and 6C).
Vaccination with DNA encoding Ag85A from M. tuberculosis or
from M. ulcerans delayed onset of foot pad swelling by only 2 to 3
weeks (Figure 6A). DNA prime/protein boost protocol using the
M. tuberculosis Ag85A did not increase vaccine efficacy (Figure 6C)
whereas vaccination with DNA encoding Ag85A from M. ulcerans
boosted with the recombinant Ag85A-MPL-A protein from M.
ulcerans delayed onset of foot pad swelling to the same extent as the
BCG vaccine by 7 to 8 weeks (Figure 6C). Survival curves reflected
the footpad swelling pattern. Median survival time of mice
Figure 1. Spleen cell IL-2 (A) and IFN-c (B) responses to RPMI medium (grey bars), recombinant Ag85A from M. ulcerans (white bars)
and M. tuberculosis (black bars) in B6 mice vaccinated with Ag85A DNA, Ag85A protein or Ag85A DNA boosted with protein in
Gerbu adjuvant, 3 months after the third immunization. Cytokines levels tested on 24 h (IL-2) and 72 h (IFN-c) culture supernatant of 4 mice
tested individually/group. Data presented as means6SDs intra-assay. Statistically significant results as compared to the DNA vaccinated M. ulcerans
or M. tuberculosis groups are represented in the figure by *** (P,0.001), ** (P,0.01) and * (P,0.05). The first group of comparison take all of the
vaccinated mice compared to the DNA vaccinated mice in response to recombinant Ag85A from M. ulcerans. The second group of comparison take
all of the vaccinated mice compared to the DNA vaccinated mice in response to recombinant Ag85A from M. tuberculosis.
doi:10.1371/journal.pntd.0000199.g001
Figure 2. Ag85 M. ulcerans specific total IgG, IgG1 and IgG2b antibody levels in B6 mice. Protein emulsified in Gerbu adjuvant. Data
represent individual antibody levels (4 mice/group), mean value is indicated by the horizontal bars. * statistical analysis showing each group with a
significant difference. For IgG1, groups c, d, f and g have a significative difference with the others groups. For IgG2b, only rec 85A Mu was
significatively different from group a and e.
doi:10.1371/journal.pntd.0000199.g002
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vaccination delayed significantly the moment when mice had to be
euthanized, resulting in a median survival time of 17.5 weeks
(Figures 6B and 6D) (p,0.001 compared to empty vector vaccinated
mice; p,0.01 compared to 85A-DNA Mu vaccinated mice). M.
ulcerans DNA vaccinated mice demonstrated a median survival time
of 13 weeks (p,0.01 compared to empty vector vaccinated mice
according to the log rank test). Similar results were observed in mice
vaccinated with DNA encoding Ag85A from M. tuberculosis (median
survival time 12.5 weeks) (Figure 6B).Boosting DNA vaccinated mice
with protein from M. tuberculosis did not increase protective efficacy of
the DNA vaccine but priming with DNA encoding Ag85A from M.
ulcerans and boosting with recombinant Ag85A from M. ulcerans was
very effective in increasing the protection (Figure 6D) (p,0.001
compared to M. ulcerans DNA alone, p,0.01 compared to DNA
encoding Ag85A from M. tuberculosis boosted with the protein of M.
tuberculosis). Median survival time in the M. ulcerans DNA primed- M.
ulcerans protein boosted mice was 17 weeks. This protection was
comparable to that conferred by BCG (p.0.05).
Discussion
Buruli ulcer belongs to the family of neglected tropical diseases
[48]. In 1998 the first International Conference on Buruli Ulcer
was organized in Co ˆte d’Ivoire, expressing the poor knowledge
about this disease and calling on the international scientific
community to support control and research efforts. Currently, no
specific vaccine exists against this disease. In 1957, Fenner
demonstrated that a high degree of protection was conferred, in
an experimental mouse model, against challenge infection with
small doses of M. ulcerans by prior inoculation with M. ulcerans, M.
balnei and M. bovis BCG (BCG). Footpad and intravenous BCG
administration gave considerable protection against a small dose
and a slight protection against a large dose of M. ulcerans given in
the other footpad [49]. More recently we have shown in a similar
experimental mouse model that BCG vaccine protects to some
extent against infection with M. ulcerans but that a booster
vaccination with the same BCG vaccine does not increase the
protective effect [31,47]. In 1969, a clinical study performed in
Figure 3. Spleen cell IL-2 (A) and IFN-c (B) responses to whole Ag85A- M. ulcerans and its synthetic peptides, as tested on a pool of
six B6 mice vaccinated 3 times at three weeks interval with Ag85A-DNA M. ulcerans (white bars) or Ag85A-DNA M. tuberculosis (black
bars). Graph in insert represents the cytokine production in response to partial Ag85A M. ulcerans aa 17–150. Unstimulated cells (grey bars). Data of
insert represent mean6SD values of 3 mice tested individually.
doi:10.1371/journal.pntd.0000199.g003
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However, protection turned out to be short-lived and was only
detected in the first 6 months following BCG vaccination [24]. In
1976, Smith et al reported another BCG vaccination trial against
Buruli ulcer in Uganda giving similar short lived (one year)
protection rates of about 50% [25]. Although not very effective at
preventing the classical skin lesions of Buruli ulcer, the BCG
vaccine seems to exert a significant protective effect against its
severe, disseminated osteomyelitis form both in children and in
adults [26,27].
Figure 4. Spleen cell IL-2 (A) and IFN-c (B) responses to whole Ag85A-M. tuberculosis and its synthetic peptides in a pool of six B6
mice vaccinated, at three weeks interval with Ag85A-DNA M. ulcerans (white bars) or Ag85A-DNA M. tuberculosis (black bars).
doi:10.1371/journal.pntd.0000199.g004
Table 1. Immunodominant peptides of Ag 85 A from M. ulcerans and M. tuberculosis.
Peptides : aa Sequences of M. ulcerans* Sequences of M. tuberculosis
21–40 NIKVQFQSGGANSPALYLLD DIKVQFQSGGANSPALYLLD
61–80 yyqsgisvampvggqssfys YDQSGLSVVMPVGGQSSFYS
81–100 dwynpacgkagcttykwetf DWYQPACGKAGCQTYKWETF
141–160 dqfvysgslsalldpsqgig QQFVYAGAMSGLLDPSQAMG
240–259 FQAAYNAAGGHNAVWNFDDN 85A :FQDAYNAGGGHNGVFDFPDS
85B :FQDAYNAAGGHNAVFNFPPN
261–280 thsweywgaqlnamrpdlqh THSWEYWGAQLNAMKPDLQR
275–294 rpdlqhtlgatpntgdtqga KPDLQRALGATPNTGPAPQGA
*Bold Amino Acids are high conserved amino acid differences (determined according to the Needleman-Wunsh criterion) and Amino Acids underlined are the non-
conserved aa difference in comparison to the Ag85A peptides of M. tuberculosis.
doi:10.1371/journal.pntd.0000199.t001
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control this debilitating disease that affects particularly children.
Unfortunately, the nature of the protective immune response and
the precise antigens involved are not fully defined at the moment.
Based on biopsy specimens, M. ulcerans was originally thought to
reside exclusively as free extracellular bacilli, implying that
humoral responses might be protective. However, Coutanceau et
al recently demonstrated that the initial phase of M. ulcerans
infection proceeds by internalization of bacilli by phagocytic cells
and that the extracellular stage results from mycolactone inducing
host cell death [6,50]. Therefore, recognition of the early
intracellular stage by an effective Th1 type immune response
may contribute to the control of the infection, that is in so far as it
can help to reduce the mycolactone production. Hence,
magnitude of mycobacteria-specific Th1 type immune response
is a plausible correlate of protection that can be used to analyze the
potential of new, experimental vaccines.
In this study, we focused on a plasmid DNA vaccine encoding
Ag85A from M. ulcerans. Protective efficacy was evaluated using
two approaches, in one experiment by enumerating the number of
AFB in the footpad at nine weeks after M. ulcerans challenge and in
the other experiment by monitoring footpad swelling and long
term survival of the mice. We have previously reported that
footpad swelling is correlated with bacterial replication and can be
used as an alternative read-out for protection against infection
[47]. DNA prime–protein boost strategy using specific M. ulcerans
antigen 85A was clearly the most effective, reducing about one
hundred fold the bacterial number and offering a protection of
Figure 5. Mycobacterial multiplication in mice infected with M.
ulcerans strain 04-855. Mice infected three months after the last
vaccination (protocol 1 using Gerbu adjuvant). Results are mean6SD of
AFB/ml of 4 individual mice, expressed in Log10. * p value as compared
to mean log10 value obtained in control DNA mice infected with M.
ulcerans.
doi:10.1371/journal.pntd.0000199.g005
Figure 6. Evaluation of footpad size (A and C) and Survival curves (B and D) of vaccinated B6 mice after M. ulcerans infection with
10
5 AFB in the right footpad. Experiment 2 using MPL-A as adjuvant and 6 weeks as rest between vaccination and infection. Mice were
vaccinated with empty vector (* n=9), with 0.2 mg of BCG (n n=10), with Ag85-DNA from M. ulcerans (% n=9), with DNA encoding 85A from M.
tuberculosis (# n=10), with Ag85A DNA-M. ulcerans boosted with the Ag85A protein from M. ulcerans (& n=9), or with DNA encoding Ag85A
boosted with Ag85 protein from M. tuberculosis ($ n=10).
doi:10.1371/journal.pntd.0000199.g006
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Nevertheless, and as for the BCG vaccine, immune protection was
not sterilizing and eventually all mice developed footpad swelling.
We hypothesize that the vaccines reduced or delayed temporarily
mycolactone production by the virulent type 1 strain 04-855 but
that immunity was not strong enough to completely block the ML
synthesis. Targeting ML production by specific antibodies or by
interfering with its synthesis might help to overcome this problem.
A study made by Fenner, in 1956 showed that the apparition of
footpad swelling depends of the number of viable AFB in the
inoculum, small doses of bacilli showing delayed appearance of
footpad lesion [51]. As we used a high inoculum size of 10
5 AFB in
our studies, it is possible that more sustained protections could
have been observed if we had administered a lower number of
bacteria.
The Gerbu adjuvant is less well known as immunomodulator
than other adjuvants such as alumn or monosphoshoryl-lipd-A
(MPL-A) [52]. Here we have shown that this adjuvant has a strong
Th1 inducing capacity, as indicated by the elevated levels of
antigen-specific IL-2 and IFN-c that could be detected in spleen
cell cultures from mice vaccinated with protein in this adjuvant.
Antibodies of both IgG1 but also of IgG2b isotype were induced,
which was another indication of its Th1 favouring properties.
Vaccination with recombinant M. ulcerans Ag85A protein in Gerbu
adjuvant induced comparable Th1 cytokine and antibody levels as
the prime-boost DNA vaccination. This protein vaccine also
induced considerable protection (albeit somewhat lower that the
DNA based vaccine) as indicated by significantly reduced number
of AFB in the footpad at nine weeks after M. ulcerans challenge. We
have previously shown that DNA vaccination induces a broader T
cell repertoire (more protein epitopes recognized) than infection
with tuberculosis [53,54], vaccination with BCG [44] or with
protein [46] and this may explain the better protection conferred
by the DNA prime-protein boost vaccination. It is also possible
that immune memory induced with this combined immunization
protocol was stronger and longer lasting than immune memory
induced with protein only vaccination.
Analysis of the H-2
b restricted Th1 T cell epitopes of antigen
85A from M. ulcerans and from M. tuberculosis revealed some extent
of species specificity, both in the NH2-terminal and in the COOH-
terminal half of the protein. In contrast to the response induced
with DNA encoding M. tuberculosis Ag85A, which was preferen-
tially directed against Ag85A peptide spanning aa 261–280, T cell
response induced with DNA encoding the M. ulcerans protein was
directed preferentially against peptide spanning aa 240–259.
Remarkably, mice vaccinated with the M. tuberculosis DNA reacted
more strongly to this peptide region of M. ulcerans (25,000 cpm of
IL-2/5,000 pg of IFN-c) than to the same region in M. tuberculosis
(10,000 cpm of IL-2/1,000 pg of IFN-c). We have previously
reported that B6 mice vaccinated with DNA encoding Ag85B
from M. tuberculosis also react more strongly to 85B peptide
spanning aa 244–260 than to peptide spanning aa 262–279 [46].
Sequence analysis of the 241–260 region of Ag85 revealed that the
Ag85A sequence from M. ulcerans is more similar to the Ag85B
sequence of M. tuberculosis (only 1 aa (A–D) change in position 242)
than to the Ag85A sequence of M. tuberculosis (4 aa changes).
Interestingly, it was demonstrated by Yanagisawa et al that
vaccination of B6 mice with killed M. tuberculosis triggered
preferentially a vb11+ CD4+ T cell response against the peptide
spanning amino acids 240 to 254 of Ag85B [55]. All these data
taken together seem to indicate that the M. ulcerans Ag85A241–260
region is more immunogenic than the corresponding M. tuberculosis
Ag85A region and this may explain the better protective efficacy
that we have observed with the species specific M. ulcerans vaccine.
In conclusion, our results show that specific Ag85A-DNA
priming followed by protein boosting is an effective way to induce
robust Th1 type immune responses and strong protection against
experimental footpad infection with M. ulcerans in mice. This is a
promising vaccination approach that warrants further analysis.
Combination with vaccines targeting mycolactone or with
vaccines targeting enzymes involved in mycolactone synthesis
may be a way to strengthen its protective efficacy.
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